Wedge Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Wedge Capital Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-87,487	Closed	-$28.7M	–	518
2024 Q4	$28.7M	Buy	+87,487	New	+$29.7M	0.52%	69
2023 Q3	–	Sell	-79,426	Closed	-$30.1M	–	492
2023 Q2	$30.1M	Buy	+79,426	New	+$32.3M	0.48%	66
2015 Q3	–	Sell	-4,375	Closed	-$659K	–	589
2015 Q2	$659K	Buy	4,375 +825	+23%	+$118K	0.01%	397
2015 Q1	$480K	Buy	3,550 +600	+20%	+$74.4K	﹤0.01%	454
2014 Q4	$356K	Buy	+2,950	New	+$340K	﹤0.01%	489

Other funds holding BIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wedge Capital Management's BIO Position: Q1 2025 in Review

Wedge Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2025, closing a stake of 87,487 shares — an estimated $28.7M sold.

Wedge Capital Management first reported a position in BIO in Q4 2014 and held it in 5 quarters. The position peaked at $30.1M in Q2 2023. 435 funds tracked by Wall St. Rank hold BIO as of Q1 2025.

Wedge Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q1 2025 after selling out during the quarter.
Wedge Capital Management sold 87,487 Bio-Rad Laboratories Class A shares in Q1 2025, an estimated $28.7M.
Wedge Capital Management first reported a position in Bio-Rad Laboratories Class A in Q4 2014 and held it in 5 quarters.
Wedge Capital Management's Bio-Rad Laboratories Class A position peaked at $30.1M in Q2 2023.
435 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2025.

Based on Wedge Capital Management's 13F filing for Q1 2025, filed 14 Apr 2025.